Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.

Karolina Boman; Anna H Larsson; U Segersten; E Kuteeva; Henrik Johannesson; Björn Nodin; Jakob Eberhard; M Uhlén; P-U Malmström; Karin Jirström

doi:10.1038/bjc.2013.215

Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.

Karolina Boman, Anna H Larsson, U Segersten, E Kuteeva, Henrik Johannesson, Björn Nodin, Jakob Eberhard, M Uhlén, P-U Malmström, Karin Jirström

Research output: Contribution to journal › Article › peer-review

Abstract

Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR=2.25 in Cohort I and 3.10 in Cohort II, adjusted HR=2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR=4.36, adjusted HR=2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR=6.19, adjusted HR=4.60) and DSS (unadjusted HR=8.34, adjusted HR=7.16).Conclusion:Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.British Journal of Cancer advance online publication, 7 May 2013; doi:10.1038/bjc.2013.215 www.bjcancer.com.

Original language	English
Pages (from-to)	2321-2328
Journal	British Journal of Cancer
Volume	108
Issue number	11
DOIs	https://doi.org/10.1038/bjc.2013.215
Publication status	Published - 2013

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Pathology, (Lund) (013030000), Oncology, MV (013035000)

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2013.215

http://www.ncbi.nlm.nih.gov/pubmed/23652315?dopt=Abstract

1 Doctoral Thesis (compilation)

A valuable pair - candidate biomarkers RBM3 and PODXL in urothelial bladder cancer
Granfelt Boman, K., 2017, Lund: Lund University: Faculty of Medicine. 74 p.
Research output: Thesis › Doctoral Thesis (compilation)

Open Access
File

Cite this

@article{594512329eb4425f8401661993b0f9fa,

title = "Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.",

abstract = "Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR=2.25 in Cohort I and 3.10 in Cohort II, adjusted HR=2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR=4.36, adjusted HR=2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR=6.19, adjusted HR=4.60) and DSS (unadjusted HR=8.34, adjusted HR=7.16).Conclusion:Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.British Journal of Cancer advance online publication, 7 May 2013; doi:10.1038/bjc.2013.215 www.bjcancer.com.",

author = "Karolina Boman and Larsson, {Anna H} and U Segersten and E Kuteeva and Henrik Johannesson and Bj{\"o}rn Nodin and Jakob Eberhard and M Uhl{\'e}n and P-U Malmstr{\"o}m and Karin Jirstr{\"o}m",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000), Oncology, MV (013035000)",

year = "2013",

doi = "10.1038/bjc.2013.215",

language = "English",

volume = "108",

pages = "2321--2328",

journal = "British Journal of Cancer",

issn = "1532-1827",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.

AU - Boman, Karolina

AU - Larsson, Anna H

AU - Segersten, U

AU - Kuteeva, E

AU - Johannesson, Henrik

AU - Nodin, Björn

AU - Eberhard, Jakob

AU - Uhlén, M

AU - Malmström, P-U

AU - Jirström, Karin

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000), Oncology, MV (013035000)

PY - 2013

Y1 - 2013

N2 - Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR=2.25 in Cohort I and 3.10 in Cohort II, adjusted HR=2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR=4.36, adjusted HR=2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR=6.19, adjusted HR=4.60) and DSS (unadjusted HR=8.34, adjusted HR=7.16).Conclusion:Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.British Journal of Cancer advance online publication, 7 May 2013; doi:10.1038/bjc.2013.215 www.bjcancer.com.

AB - Background:Membranous expression of the anti-adhesive glycoprotein podocalyxin-like (PODXL) has previously been found to correlate with poor prognosis in several major cancer forms. Here we examined the prognostic impact of PODXL expression in urothelial bladder cancer.Methods:Immunohistochemical PODXL expression was examined in tissue microarrays with tumours from two independent cohorts of patients with urothelial bladder cancer: n=100 (Cohort I) and n=343 (Cohort II). The impact of PODXL expression on disease-specific survival (DSS; Cohort II), 5-year overall survival (OS; both cohorts) and 2-year progression-free survival (PFS; Cohort II) was assessed.Results:Membranous PODXL expression was significantly associated with more advanced tumour (T) stage and high-grade tumours in both cohorts, and a significantly reduced 5-year OS (unadjusted HR=2.25 in Cohort I and 3.10 in Cohort II, adjusted HR=2.05 in Cohort I and 2.18 in Cohort II) and DSS (unadjusted HR=4.36, adjusted HR=2.70). In patients with Ta and T1 tumours, membranous PODXL expression was an independent predictor of a reduced 2-year PFS (unadjusted HR=6.19, adjusted HR=4.60) and DSS (unadjusted HR=8.34, adjusted HR=7.16).Conclusion:Membranous PODXL expression is an independent risk factor for progressive disease and death in patients with urothelial bladder cancer.British Journal of Cancer advance online publication, 7 May 2013; doi:10.1038/bjc.2013.215 www.bjcancer.com.

U2 - 10.1038/bjc.2013.215

DO - 10.1038/bjc.2013.215

M3 - Article

C2 - 23652315

SN - 1532-1827

VL - 108

SP - 2321

EP - 2328

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 11

ER -

Membranous expression of podocalyxin-like protein is an independent factor of poor prognosis in urothelial bladder cancer.

Abstract

Bibliographical note

Subject classification (UKÄ)

UN SDGs

Access to Document

Fingerprint

Research output

A valuable pair - candidate biomarkers RBM3 and PODXL in urothelial bladder cancer

Cite this